Study | Year | Country | Tumour type | N | Detected sample | Stage I/II/III/IV | Lymph node −/+ | Follow-up months | miR-146a assay | Cut-off | HR (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|
Hess | 2017 | Germany | HNSCC | 149 | Tissue | 0/0/0/149 | NR | Median 61 | qRT-PCR | Median | 0.450 (0.230–0.830) |
LUO | 2017 | China | GC | 93 | Tissue | 0/0/42/51 | 17/76 | NR | qRT-PCR | 2.0 | 0.129 (0.028–0.601) |
Zavala | 2016 | Chile | TNBC | 39 | Tissue | NR | 20/19 | NR | qRT-PCR | Median | 0.130 (0.026–0.650) |
Li | 2014 | China | NSCLC | 43 | Tissue | NR | NR | NR | MISH & qRT-PCR | Median | 2.930 (1.440–5.960) |
Chen | 2013 | China | NSCLC | 101 | Tissue | (I/II:28) (III/IV:73) | 35/66 | NR | qRT-PCR | Mean | 0.420 (0.180–0.950) |
Zhong | 2012 | China | DLBCL | 90 | Tissue | 9/31/24/26 | NR | Mean 26.3 | qRT-PCR | Optimal | 1.119 (0.977–1.282) |
Hou | 2012 | China | GC | 43 | Tissue | 8/11/18/6 | 14/29 | NR | qRT-PCR | Median | 0.280 (0.100–0.750) |
Paik | 2011 | Korea | NK/T | 50 | Tissue | 26/11/0/13 | 43/7 | NR | qRT-PCR | Optimal | 0.076 (0.019–0.300) |
Kogo | 2011 | Japan | GC | 90 | Tissue | 27/18/23/22 | 30/60 | Mean 36 | qRT-PCR | Median | 0.650 (0.440–0.940) |
Wang | 2010 | China | ALL | 32 | Bone marrow | NR | NR | NR | qRT-PCR | Median | 1.690 (1.040–2.760) |
Wang | 2010 | China | AML | 53 | Bone marrow | NR | NR | NR | qRT-PCR | Median | 1.560 (1.120–2.170) |